June 28, 2022 08:52 AM EDT

Years after linking arms with Bristol Myers and both Mercks, Sutro finds its latest partner in Tokyo

Kyle LaHucik

Senior Reporter

Astellas and Sutro Biopharma are linking arms on a new field of antibody-drug conjugates that they hope will improve upon existing cancer immunotherapies.

The Tokyo …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Years after linking arms with Bristol Myers and both Mercks, Sutro finds its latest partner in Tokyo

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Avid Bioservices to be sold to private equity firms for $1.1B

Denali teases early data for enzyme replacement therapy in rare disease

Genmab chops early cancer prospects to prioritize Phase 3 projects

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Years af­ter link­ing arms with Bris­tol My­ers and both Mer­cks, Sutro finds its lat­est part­ner in Tokyo

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

De­nali teas­es ear­ly da­ta for en­zyme re­place­ment ther­a­py in rare dis­ease

Gen­mab chops ear­ly can­cer prospects to pri­or­i­tize Phase 3 projects

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Years after linking arms with Bristol Myers and both Mercks, Sutro finds its latest partner in Tokyo

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Avid Bioservices to be sold to private equity firms for $1.1B

Denali teases early data for enzyme replacement therapy in rare disease

Genmab chops early cancer prospects to prioritize Phase 3 projects

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks